Literature DB >> 7841036

Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor.

L Trentin1, R Zambello, P Bulian, A Cerutti, C Enthammer, M Cassatella, D Nitti, M Lise, C Agostini, G Semenzato.   

Abstract

Tumour necrosis factor alpha (TNF-alpha) is a cytokine with a variety of immunological properties. The identification of two receptors for this molecule, i.e. the 75 kDa and the 55 kDa TNF receptors (TNF-R), recently clarified the mechanisms through which this cytokine provides its wide range of immunomodulatory activities. In this study we have investigated the expression and the functional properties of these receptors on tumour-infiltrating lymphocytes (TILs) recovered from 17 patients with solid cancers (melanoma, colorectal carcinoma and lung cancer). To this end, TIL lines and freshly isolated TILs were evaluated for (a) the expression and the functional role of TNF receptors following culture in the presence of interleukin 2 (IL-2) and (b) the production of TNF-alpha following culture with IL-2 and the role of this cytokine in IL-2-driven TIL proliferation. Flow cytometry analysis demonstrated that TILs bear the 75 kDa TNF-R. Moreover, TIL lines express detectable messages for TNF-alpha and release this cytokine. Functional in vitro studies have shown that anti-TNF-alpha, as well as anti-75 kDa TNF-R antibodies, are able to inhibit the IL-2-induced TIL proliferation. These data demonstrate that TILs are equipped with a fully functional TNF-R system and suggest a putative role for this receptor and its ligand in the activation and expression of TILs following immunotherapy with IL-2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7841036      PMCID: PMC2033576          DOI: 10.1038/bjc.1995.50

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  43 in total

1.  Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses.

Authors:  P Scheurich; B Thoma; U Ucer; K Pfizenmaier
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

2.  Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.

Authors:  M E Ostensen; D L Thiele; P E Lipsky
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

3.  Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

Authors:  L M Muul; P J Spiess; E P Director; S A Rosenberg
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

4.  Role of tumor necrosis factor-alpha and its specific 55-Kd and 75-Kd receptors in patients with lymphoproliferative disease of granular lymphocytes.

Authors:  R Zambello; L Trentin; P Bulian; M Cassatella; R Raimondi; T Chisesi; C Agostini; G Semenzato
Journal:  Blood       Date:  1992-10-15       Impact factor: 22.113

5.  Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders.

Authors:  L Trentin; R Zambello; C Agostini; F Siviero; F Adami; R Marcolongo; R Raimondi; T Chisesi; G Pizzolo; G Semenzato
Journal:  Blood       Date:  1993-02-01       Impact factor: 22.113

6.  Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors.

Authors:  M R Shalaby; B B Aggarwal; E Rinderknecht; L P Svedersky; B S Finkle; M A Palladino
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

7.  Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.

Authors:  K Itoh; A B Tilden; C M Balch
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

8.  Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes.

Authors:  M C Cuturi; M Murphy; M P Costa-Giomi; R Weinmann; B Perussia; G Trinchieri
Journal:  J Exp Med       Date:  1987-06-01       Impact factor: 14.307

9.  Functional role of IL-2 receptors on tumour-infiltrating lymphocytes.

Authors:  L Trentin; R Zambello; P Bulian; A Cerutti; A Milani; E Pirone; D Nitti; C Agostini; G Semenzato
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

10.  Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.

Authors:  G E Ranges; I S Figari; T Espevik; M A Palladino
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  6 in total

Review 1.  The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  Immunology       Date:  2011-06-02       Impact factor: 7.397

2.  The diverse roles of the TNF axis in cancer progression and metastasis.

Authors:  Boram Ham; Maria Celia Fernandez; Zarina D'Costa; Pnina Brodt
Journal:  Trends Cancer Res       Date:  2016-01-01

3.  Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.

Authors:  T Z Zaks; D B Chappell; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

4.  Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.

Authors:  Xin Chen; Jeffrey J Subleski; Heather Kopf; O M Zack Howard; Daniela N Männel; Joost J Oppenheim
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

5.  IP6 reduces colorectal cancer metastasis by mediating the interaction of gut microbiota with host genes.

Authors:  Tong-Tong Lan; Yang Song; Xiao-Han Liu; Cui-Ping Liu; Hui-Chao Zhao; Yi-Sa Han; Chu-Hui Wang; Ning Yang; Zhen Xu; Meng Tao; Hui Li
Journal:  Front Nutr       Date:  2022-09-02

6.  Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.

Authors:  Geoffrey S Williams; Bina Mistry; Sandrine Guillard; Jane Coates Ulrichsen; Alan M Sandercock; Jun Wang; Andrea González-Muñoz; Julie Parmentier; Chelsea Black; Jo Soden; Jim Freeth; Jelena Jovanović; Rebecca Leyland; Rafia S Al-Lamki; Andrew J Leishman; Steven J Rust; Ross Stewart; Lutz Jermutus; John R Bradley; Vahe Bedian; Viia Valge-Archer; Ralph Minter; Robert W Wilkinson
Journal:  Oncotarget       Date:  2016-10-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.